Click on a company name to read more:
1st Dental Laboratories plc is an AIM listed company. Its products are in the sectors of prosthetics, orthodontics as well as crown and bridge works.
Abcam plc is a producer and distributor of research-grade antibodies and associated products. Its catalog exceeds 45,000 products.
ActiveHealth's CareEnginesm Service is a sophisticated, knowledge-loaded technology platform that utilizes evidence-based medicine to identify and stratify patient risk based upon claims, pharmacy, laboratory and UM data collected from the continuum of care.
The CareEngine Service combs through high volumes of patient claims, pharmacy, laboratory, and hospital data and applies a series of clinical algorithms, or "Clinical matrices" designed to identify cases in which there may be a problem with the current course of treatment, or a medical problem that is not being addressed.
InvestCare Partners exited its investment in ActiveHealth in May 2005.
Altacor is an Ophthalmology Specialty Pharmaceutical Company which develops and markets differentiated products directed to the needs of both ophthalmologists and patients. Altacor uses its drug development skills and in depth market knowledge to build a portfolio of high quality, differentiated prescription medicines that set new standards in the sector. Altacor's pipeline consists of development and in-licensed products which address Ocular Surface Disease, Ocular Infection and Glaucoma.
AMICAS is a seasoned Healthcare Information Technology (HIT) company that develops, markets and sells the first complete Internet-based alternative to medical X-ray film. AMICAS software only solution competes in the space known as Picture Archive and Communication (PAC) systems.
During the past five years AMICAS has gained market share with a customer base approaching 100 that includes Massachusetts General Hospital, New York’s Columbia Presbyterian Medical Center, New York Weill Cornell Medical Center, Boston Medical Center, University of Chicago Hospitals, Michigan State University and dozens of other leading healthcare facilities.
Investcare Partners exited its investment in Amicas in November 2003.
Amura is a structure-based drug discovery business specialising in diseases such as osteoporosis, osteoarthritis, bone metastasis, autoimmunity, chronic pain and malaria. Amura has a proprietary technology platform (AMcore™) that provides a turnkey solution for the discovery of small-molecule inhibitors against cysteine peptidases (cathepsin enzymes); which are commercially attractive therapeutic targets. Amura compounds possess highly desirable drug-like properties; thereby facilitating the rapid and innovative discovery of orally active pharmaceutical ingredients across several disease areas.
Animas Corp. provides products and services for patients with Type 1 diabetes to better manage their disease, reduce long-term morbidity, and to lower costs to the patients and healthcare system. The company's primary efforts are focused on making diabetes management easier for both the patient and healthcare provider through product innovation, customer support, and superior customer education.
Animas launched its first product, the R1000 insulin infusion pump in July 2000 and its next generation pump, the IR1000, in September 2002. Additional products under development include: the ezManager software system, novel insulin infusion sets and an implantable continuous glucose monitor. The long-term vision of the company is to ultimately combine the pump and sensor in a single closed loop device.
InvestCare Partners exited its investment in Animas in December 2005.
BioVex is a biotechnology company focused on the development and commercialization of a new class of potent biologics for the treatment of cancer and prevention of infectious disease. The Company’s lead cancer technology platform, OncoVEX GM-CSF is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEX GM-CSF works by: replicating and spreading within solid tumors, causing the death of cancer cells; while stimulating the immune system to destroy metastatic deposits.
Chromogenex PLC is the UK’s leading developer and manufacturer of laser and intense pulsed light (IPL) systems. Since 1985, Chromogenex PLC has been at the forefront of laser and light technology for aesthetic applications such as laser hair removal, skin rejuvenation, acne treatment, IPL Laser and vascular lesions. In 1994, the company developed and patented the world’s first Ruby laser for permanent hair reduction.
Craneware, Inc. is a leading supplier of business intelligence and revenue cycle software that provides clients with chargemaster management software and products designed to optimize legitimate reimbursements and assist in managing the revenue cycle through better information, workflow, pricing strategy, capture of lost revenue and best practice modeling.
Crothall is a principal supplier of specialized facilities management services to hospitals, universities and commercial clients throughout the United States and Canada.
By providing specialized management expertise in the areas of facilities engineering, housekeeping, laundry and linen, patient transportation, and energy and asset management,
Investcare Partners exited its Crothall investment in August 2001.
deltaDOT Ltd. is a Life Science company focused on developing and commercialising innovative enabling technologies for the separation and analysis of biomolecules. deltaDOT was founded in 2000 and is a spin out from Imperial College of Science, Technology and Medicine, London. The company is focused on harnessing the cutting edge technologies developed in the Department of High Energy Physics and their application to biomolecular separation and analysis.
deltaDOT's core label free analysis technology, coupled with proprietary software algorithms, forms the technical basis of deltaDOT's products. deltaDOT label free technology enables higher quality and faster separations from existing separation technologies. The increased performance enabling the direct monitoring of unlabelled biomolecules, reducing the cost per analysis compared to conventional methods. deltaDOT addresses biomolecular separation applications within pharmaceutical, biotechnology, biodefence, food and drink quality, forensic science, diagnostic and academic markets.
Digital Healthcare delivers software solutions that address some of the World's fastest growing healthcare issues. Founded to provide image management and storage solutions for the Ophthalmology sector, the company has extended its product range and expanded into new International territories based on its core competencies in Clinical Information and Patient Care Management and is now a leading provider to the NHS in the UK, a major supplier to US physicians and has solutions in use within some of the Worlds' leading Eye Institutions.
gloStream provides physicians and healthcare facilities with electronic medical record and practice management solutions delivered and supported through a nationwide network of local technology partners. gloStream products are secure, easy-to-use applications and the only integrated EMR/PM solutions on the market embedded with Microsoft Office. Through a simple user interface, robust voice recognition technology, and single-click access to all patient information, gloStream products help doctors improve patient care by streamlining workflow and creating efficiencies in office administration. gloEMR™ version 4.0 from gloStream is a CCHIT Certified® product for CCHIT Ambulatory EHR 2007.
Immunodiagnostic Systems Holdings plc (IDS) is dedicated to the development and provision of innovative immunoassays for use in clinical and research laboratories worldwide. The Company is focused on creating and sustaining its position as a leading specialist in in-vitro diagnostics, building an enviable capability in de novo product design, development, manufacture and marketing.
InforSense provides a suite of highly agile, predictive and visual enterprise business intelligence and reporting software. InforSense was founded in 1999 to commercialize pioneering, award-winning technology in the fields of High Performance Computing and Large Scale Data Mining developed at Imperial College, London.
InforSense’s core expertise lies in the development of a generic, horizontal, high performance business and scientific intelligence and Web-based reporting platform. This platform enables organizations to integrate, automate and visualize data sources, information and analysis processes to deliver significantly improved productivity, performance and breakthrough predictive insights.
IS Pharma (International Speciality Pharmaceuticals) develops, acquires and commercialises late-stage pharmaceuticals and medical devices,focusing in critical care, oncology and neurology. Based in the UK, IS Pharma commercialises its portfolio in the UK directly and internationally through a strong network of distributors.
Fisher Consulting was founded in 1989 to help extend and enhance the performance of cutting-edge medical equipment, while reducing service and replacement costs. In the past 15 years, the company has become a highly respected capital asset management firm. Fisher helps protect its clients' significant investments in equipment by not only advising on equipment purchases, but also by providing maintenance, repair and monitoring services for sophisticated technical medical diagnostic and monitoring equipment used by healthcare institutions.
Fisher's Clinical Engineering Solutions includes a host of clinical engineering services - all of which help ensure hospital equipment is installed correctly, safely operated, and well-utilized. Other consulting programs such as lifecycle costing, pre-purchase analysis, and installation planning, are helping hospitals achieve greater operational efficiencies and reduce overhead.
Health Hero Network develops and markets a technology platform for remote patient monitoring. Leading healthcare product and service providers offer programs based on the Health Hero platform® to communicate with, educate, and monitor patients with a variety of conditions including heart disease, diabetes, respiratory disease, mental health, and post-acute care. By identifying changes in a patient's health condition more rapidly, The Health Hero platform enables caregivers to focus attention on those most in need of intervention, a factor that has a tremendous impact on reducing healthcare spending while improving quality of care. The company also is licensing its platform to medical device and pharmaceutical companies seeking to enable new service and revenue opportunities from disease management or to enhance clinical research.
The company has protected its pioneering work in patient communications technologies over the past decade with a portfolio of more than 30 patents.
InvestCare Partners exited its investment in Health Hero Network in December 2007.
Bold indicates a current portfolio company
InTouch Health, Inc., founded by medical robotics pioneer Yulun Wang, Ph.D., provides technology solutions which dramatically increase the effectiveness of healthcare professionals. The company is addressing the impending demographic crisis in senior care support by pioneering the use of Remote Presence in healthcare with its "Companion" system. Through a proprietary communications and mobile robotic platform, caregiving experts are projected to another setting where a patient or caregiver is located to provide care, coach and train staff, or monitor healthcare services. The InTouch Health solution leverages the time and expertise of healthcare professionals across multiple care facilities, improving the efficiency and effectiveness of care delivery.
Applications for InTouch Health's innovative medical technology include remote patient monitoring by experts in other parts of the country and shoring-up scarce nursing resources. There are currently over 400,000 unfilled nursing positions in the country.
MediGene applies state-of-the-art technologies in the development of innovative drugs for the treatment of cancer and autoimmune diseases. The company pursues the strategy of integrating all core areas of a modern biopharmaceuticals company from research to drug development and commercialization.
Medsite is an e-marketing service provider to pharmaceutical and healthcare companies. Through its Internet-based programs, Medsite connects companies with its extensive healthcare provider database. The Company's primary service, Medsite Rewards Program(tm), has reached over 400,000 physicians.
Medsite uses the power of the Internet to provide a full suite of online marketing and educational services that broaden reach, cement relationships, and deliver rewards to physicians. Over the years, Medsite has forged strong relationships with physicians by offering user-friendly, high quality products on its Web site, and by offering medically relevant gifts through Medsite Rewards. Medsite has reached over 200,000 physicians through its Medsite Rewards program, and has transactional online relationships with over 125,000 physicians and 50,000 medical students.
InvestCare Partners exited its investment in Medsite in September 2006.
MDeverywhere is a mobile computing platform providing healthcare solutions at the point of care to increase the efficiency of physician billing and documentation. It provides automated physician encounter capture services for healthcare providers at the point of care. Using a PDA and the Company's charge capture program, EveryCharge(sm), physicians can avoid the error-prone and expensive paper-based billing process.
MDEverywhere was acquired by Med-e-Manager in 2003.
MedVantx has developed a comprehensive point-of-care pharmaceutical management and automated medication dispensing system. The Company's web-enabled system automates the distribution chain and control of physician-administered medications, drug company samples, OTC products and first prescription medications at the point-of-care.
The MedVantx approach is based on turning complex processes into streamlined systems that provide physician convenience and high-quality care for the patient. It delivers prescriptions in the healthcare provider's office, at the point of diagnosis, exactly as the physician recommended. This provides the opportunity to discuss dosing, potential side effects, and any specific recommendations about a particular drug.
MedVantx also provides patient benefit information to the physician at the point of prescription. Information that helps physicians prospectively choose the right medication - formulary compliant and clinically safe. It is compatible with many e-Prescribing tools.
Omni Dental Sciences Ltd is the holding company for two trading companies — Oraldent Limited which develops and sells oral care products and Professional Dental Supplies Ltd which sells cross infection products.The core business is to provide high added value dental products where there is a proven market and scientific support for the products.
Onyx provides a wide range of chemical services to the life sciences and pharmaceutical industries. Its key focus is scaling up the synthesis of new chemical entities for drug development. Onyx Scientific is one of the fastest growing pharmaceutical service companies in the UK. Onyx has more than 40 expert scientists specialising in drug development from medicinal chemistry to early stage GMP production. The company’s chemistry expertise has an industry leading reputation.
Optasia makes software that facilitates the reading of x-rays for the management of musculoskeletal diseases. The company’s products are used in clinical trials and by physicians to identify and monitor patients who will benefit from treatment. With Optasia Medical's tools, medical images can be evaluated more rapidly, more accurately and more reproducibly.
PAION is a biopharmaceutical company specializing in developing and commercializing innovative drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases.
Pioneer Surgical Technology, Inc. is a dynamic medical device firm with a full line of cutting-edge motion preservation devices, either available commercially in Europe or under clinical evaluation in the U.S. Pioneer’s signature articulating P3™ Technology — Pioneer PEEK-on-PEEK, in its NuBac™ disc arthroplasty system, BacJac™ interspinous decompression system, and NuNec™ artificial cervical disc, is the most technologically advanced in the industry. Currently, Pioneer offers a diverse portfolio of next generation spinal fusion devices.
Pioneer’s focus on innovation has resulted in over 100 U.S. and Foreign patents with numerous patents pending. The company established a Biologics Division following two acquisitions in 2007. Pioneer Orthobiologics is developing a rich pipeline of products indicated for a variety of spinal and orthopaedic applications. Pioneer focuses on developing products which are easier and faster for the surgeon, cost effective for the health care system, and provide better patient outcomes.
Plum Baby is a UK premium organic baby food brand which is committed to providing ‘real food’ for babies and parents.
Population Genetics Technologies (PGT) Ltd is creating new paradigms for performing large-scale population genetics studies. This novel technology, conceived by Nobel laureate Professor Sydney Brenner, samples large populations to identify the genetic variation responsible for human disease and drug response.
PureCircle is pioneering the extraction of natural goodness from plants. Through investment in experience, innovative technology and facilities around the world the company aims to improve global health and well-being by providing natural, pure extracts which are ideal for a wide variety of food and beverage applications. PureCircle is the world’s leading developer, producer and marketer of high-purity Rebaudioside A (Reb A), the first all-natural zero calorie sweetener.
Ranir manufactures and markets consumer oral care products in North America. It offers manual and power toothbrushes, dental floss and flossers, tooth whiteners, trial-sized products, travel kits, and accessories to retailers as well as branded contract manufacturing customers.
Sinclair Pharma plc is an international specialty pharmaceutical company with proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market in a short time frame. The company focuses on niche therapeutic areas and its current portfolio includes products in dermatology and oral health.
The Steribottle Group has, after several years of development, now launched the Steri-Bottle, the world's first ready-to-use, sterile, disposable and affordable baby feeding bottle. It's made of safe plastic, and it comes complete with a special teat all pre-sterilised and ready to use. Feeding is now as simple as opening a fresh bottle, filling with chosen feed, feeding the baby and throwing away the bottle when finished.
The Steri-bottle teat has a noticeably warm and soft feel. Available in 'fast' and 'medium' flow versions, it incorporates a clever little valve that lets in just the right amount of air, allowing your baby to feed comfortably without accumulating excess wind. Steri-bottle has a helpful wise mouth for expressing breastmilk. The Steri-daptor adaptor fits one popular breast-pump, and will be available for most others. Steri-bottle can be used to store milk in your fridge or freezer without the danger of cracking.
The Steri-bottle represents a fundamental development and paradigm shift in the FMCG (fast-moving consumer goods) marketplace that has the potential to become as ubiquitous as the disposable nappy. The Steri-bottle has been developed over the past five years from an idea into a complete business platform being commercialised internationally.
Vectura Group plc is a product development company focused on the development of inhaled therapies principally for the treatment of respiratory diseases. Vectura develops products to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). The company also develops products for non-respiratory diseases, where optimised delivery via the lungs could provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.
YORK PHARMA PLC is a pharmaceutical Group which markets and supplies branded prescription products to pharmaceutical wholesalers, hospitals and general practitioners within the field of dermatology. The Group currently has at its disposal more than 20 patent families (with over 100 individual patents/patent applications) and intellectual property in relation to its portfolio of novel dermatology products and technology platforms in the key therapeutic areas of fungal infection, eczema/dermatitis, psoriasis, vitiligo and acne.